Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 Return-on-Tangible-Asset is 15.76% as of Dec. 2025, which is 704% above its 10-year median of 1.96. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 1 warning sign investors should review. Among 683 Healthcare Providers & Services companies, Diaceutics ranks worse than 62.08% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Diaceutics's annualizedNet Income for the quarter that ended in Dec. 2025 was $6.69 Mil. Diaceutics's average total tangible assets for the quarter that ended in Dec. 2025 was $42.43 Mil. Therefore, Diaceutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 15.76%.
The historical rank and industry rank for Diaceutics's Return-on-Tangible-Asset or its related term are showing as below:
DIUXF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -5.45 Med: 1.96 Max: 21.82
Current: 0.3
During the past 10 years, Diaceutics's highest Return-on-Tangible-Asset was 21.82%. The lowest was -5.45%. And the median was 1.96%.
DIUXF's Return-on-Tangible-Asset is ranked worse than 62.08% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs DIUXF: 0.30
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Diaceutics Return-on-Tangible-Asset Related Terms
Diaceutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Diaceutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DIUXF vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Diaceutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Diaceutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 15.76% mean?
Diaceutics (DIUXF) has a Return-on-Tangible-Asset of 15.76% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Diaceutics and its competitors. This is 704% above median its historical median of 1.96. According to the industry distribution chart, Diaceutics ranks #424 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 62.1%.
Is Diaceutics' Return-on-Tangible-Asset too high?
Diaceutics' current Return-on-Tangible-Asset of 15.76% is 704% above median its 10-year median of 1.96. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. Diaceutics' value of 15.76% is 548.6% above this industry median. Based on the distribution chart, Diaceutics ranks #424 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #424 out of 683 companies for Return-on-Tangible-Asset. This places Diaceutics in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. Diaceutics' value of 15.76% is 548.6% above this benchmark. While the company's 10-year median is 1.96 vs. the industry median of 2.43, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Return-on-Tangible-Asset of 15.76% is 548.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Return-on-Tangible-Asset is 15.76%, which is 704% above median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $2.00 — trading 2.4% below its estimated fair value. The current Return-on-Tangible-Asset is 15.76%, which is 704% above median its 10-year median of 1.96 and 548.6% above the Healthcare Providers & Services industry median of 2.43. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Return-on-Tangible-Asset is 15.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
Return-on-Tangible-Asset: 15.76% (704% above median its 10-year median of 1.96)
GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
Industry Position: 548.6% above the Healthcare Providers & Services median (#424 of 683)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
